{"product_id":"strides-swot-analysis","title":"Strides Pharma Science SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete SWOT Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eStrides Pharma Science boasts a robust global presence and a strong pipeline, but faces intense competition and regulatory hurdles. Understanding these dynamics is crucial for strategic decision-making.\u003c\/p\u003e\n\u003cp\u003eWant the full story behind Strides Pharma Science's strengths, risks, and growth drivers? Purchase the complete SWOT analysis to gain access to a professionally written, fully editable report designed to support planning, pitches, and research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Presence and Diversified Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStrides Pharma Science boasts a significant global presence, operating in key regulated markets such as the United States, Europe, and Australia, alongside a robust footprint in emerging economies. This broad geographical diversification is a core strength, effectively reducing the company's vulnerability to downturns in any single region and enabling it to capitalize on diverse growth opportunities across the globe.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFocus on Niche and Complex Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStrides Pharma Science strategically concentrates on niche and complex generic formulations, such as injectables, softgels, and oral solids. This specialization in products that are challenging to manufacture creates significant barriers for new entrants in the market.\u003c\/p\u003e\n\u003cp\u003eThis focus on difficult-to-produce pharmaceuticals, including sterile injectables, often translates into more robust profit margins for Strides. For instance, in the fiscal year 2024, the company reported a notable increase in its revenue from complex generics, underscoring the financial benefits of this strategic direction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Manufacturing Capabilities and R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStrides Pharma Science possesses robust manufacturing capabilities, with world-class facilities strategically located in India, Italy, Kenya, and the United States. These sites have garnered approvals from stringent regulatory bodies such as the USFDA, MHRA, TGA, and WHO, underscoring their commitment to global quality standards. \u003c\/p\u003e\n\u003cp\u003eThe company's dedicated R\u0026amp;D center in Bangalore is a powerhouse of innovation, focusing on developing next-generation pharmaceutical products. This strong R\u0026amp;D infrastructure allows Strides to consistently enhance its product pipeline and maintain a competitive advantage in the dynamic pharmaceutical market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Financial Performance and Debt Reduction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStrides Pharma Science has showcased robust financial performance, marked by substantial year-on-year increases in revenue and operating profit during the fiscal years 2024 and 2025. This growth underscores the company's operational efficiency and market penetration. \u003c\/p\u003e\n\u003cp\u003eFurthermore, Strides has made significant strides in enhancing its cash flow generation and actively reducing its net debt. This strategic focus on financial health has bolstered the company's overall stability and reduced financial risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eRevenue Growth:\u003c\/strong\u003e Achieved a notable increase in revenue for FY24-25, reflecting strong market demand for its products.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOperating Profit Improvement:\u003c\/strong\u003e Demonstrated enhanced profitability through effective cost management and sales strategies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDebt Reduction:\u003c\/strong\u003e Successfully lowered its net debt levels, improving its balance sheet strength.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCash Flow Enhancement:\u003c\/strong\u003e Generated stronger operating cash flows, providing greater financial flexibility.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommitment to Sustainability and ESG\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStrides Pharma Science's dedication to sustainability is a significant strength, as evidenced by its strong performance in S\u0026amp;P Global's 2024 Sustainability Assessment. The company achieved a high Environmental, Social, and Governance (ESG) score, positioning it in the 94th percentile among its industry peers.\u003c\/p\u003e\n\u003cp\u003eThis commitment not only bolsters Strides Pharma Science's corporate reputation but also resonates with the growing demand from investors for businesses that prioritize sustainable practices. Such a focus can attract capital and foster long-term value creation by aligning with global trends and regulatory expectations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrong ESG Performance:\u003c\/strong\u003e Ranked in the 94th percentile in S\u0026amp;P Global's 2024 Sustainability Assessment.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInvestor Appeal:\u003c\/strong\u003e Aligns with increasing investor preference for sustainable and responsible businesses.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReputational Enhancement:\u003c\/strong\u003e Boosts the company's image as a forward-thinking and ethical organization.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma's Strategic Edge: Complex Generics, Global Footprint, and Financial Strength\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStrides Pharma Science's strategic focus on complex generics, such as injectables and softgels, creates a competitive advantage by targeting products with higher barriers to entry and potentially better profit margins. This specialization is supported by robust R\u0026amp;D capabilities, as demonstrated by their consistent efforts to enhance their product pipeline.\u003c\/p\u003e\n\u003cp\u003eThe company's global manufacturing footprint, with facilities approved by major regulatory bodies like the USFDA and MHRA, ensures high-quality production and market access. This diversified operational base, coupled with strong financial performance in FY24-25, including revenue growth and debt reduction, underpins its market position.\u003c\/p\u003e\n\u003cp\u003eStrides Pharma Science also exhibits a strong commitment to sustainability, achieving a high ESG score and ranking in the 94th percentile in S\u0026amp;P Global's 2024 assessment, which enhances its appeal to ethically-minded investors.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eStrength\u003c\/th\u003e\n\u003cth\u003eDescription\u003c\/th\u003e\n\u003cth\u003eSupporting Data\/Fact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal Presence\u003c\/td\u003e\n\u003ctd\u003eOperations in regulated and emerging markets reduce regional risk.\u003c\/td\u003e\n\u003ctd\u003eKey markets include US, Europe, Australia, and emerging economies.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNiche Product Focus\u003c\/td\u003e\n\u003ctd\u003eSpecialization in complex generics like injectables and softgels.\u003c\/td\u003e\n\u003ctd\u003eThese formulations present higher manufacturing challenges, creating entry barriers.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing Excellence\u003c\/td\u003e\n\u003ctd\u003eWorld-class facilities with global regulatory approvals.\u003c\/td\u003e\n\u003ctd\u003eSites in India, Italy, Kenya, US approved by USFDA, MHRA, TGA, WHO.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Performance\u003c\/td\u003e\n\u003ctd\u003eConsistent revenue growth and improved profitability.\u003c\/td\u003e\n\u003ctd\u003eSubstantial year-on-year increases in revenue and operating profit in FY24-25.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt Reduction \u0026amp; Cash Flow\u003c\/td\u003e\n\u003ctd\u003eStrengthened balance sheet and increased financial flexibility.\u003c\/td\u003e\n\u003ctd\u003eActive reduction of net debt and enhanced operating cash flow generation.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSustainability Commitment\u003c\/td\u003e\n\u003ctd\u003eStrong ESG performance and investor appeal.\u003c\/td\u003e\n\u003ctd\u003eRanked in the 94th percentile in S\u0026amp;P Global's 2024 Sustainability Assessment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eAnalyzes Strides Pharma Science’s competitive position through key internal and external factors, highlighting its strengths in manufacturing and market access alongside potential threats from regulatory changes and competition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eIdentifies critical market opportunities and potential threats, enabling proactive risk mitigation for Strides Pharma Science.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVolatility in Stock Performance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStrides Pharma Science's stock performance has been notably volatile. For instance, the company's shares saw a significant drop from their 52-week high in October 2024, even with some recent upward movement. This kind of fluctuation can signal investor uncertainty or a heightened sensitivity to both broader market trends and news specific to Strides.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of Regulatory Classifications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWhile a Voluntary Action Indicated (VAI) classification from the USFDA is typically manageable, regulatory observations, such as those received for Strides Pharma Science's Alathur facility in April 2024, can still provoke negative market sentiment and demand sustained compliance initiatives. This underscores the persistent regulatory oversight inherent in the pharmaceutical sector.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemerger of High-Margin Businesses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe demerger of Strides Pharma Science's high-margin softgel business, intended to unlock shareholder value, presents a potential weakness by temporarily impacting overall profitability. This strategic move necessitates careful management to offset any immediate dip in consolidated margins.\u003c\/p\u003e\n\u003cp\u003eFor instance, while the softgel segment was a significant contributor, its separation means the remaining businesses must absorb any operational shifts. Investors will be closely watching the 2024 and 2025 financial reports to gauge the effectiveness of these adjustments and the company's ability to maintain healthy profit margins across its diversified portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePotential for Price Erosion in Key Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eStrides Pharma Science's significant reliance on its US business presents a notable weakness. This market, a key revenue driver, is grappling with persistent price erosion, a common issue in the generics sector.  Furthermore, high inventory levels can exacerbate this pressure, potentially squeezing profit margins and necessitating ongoing strategic adjustments to safeguard market position and competitive pricing.\u003c\/p\u003e\n\u003cp\u003eThe impact of these challenges is evident in financial performance metrics. For instance, during the fiscal year ending March 31, 2024, the company's US generics segment experienced pricing pressures that affected its overall profitability. Managing these dynamics is crucial for sustained growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eUS Market Vulnerability:\u003c\/strong\u003e The US generics market is characterized by intense competition and regulatory scrutiny, leading to price erosion.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInventory Management Challenges:\u003c\/strong\u003e High inventory levels can tie up working capital and increase the risk of obsolescence, impacting financial flexibility.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProfitability Squeeze:\u003c\/strong\u003e The combination of pricing pressure and inventory issues can directly affect the profitability of Strides Pharma Science's US operations.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Imperative:\u003c\/strong\u003e Continuous strategic planning is required to navigate these headwinds and maintain a competitive edge in the US market.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliance on Generic Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eStrides Pharma Science's focus on generic formulations, while accessing broad market opportunities, places it in a highly competitive landscape, particularly within regulated markets like the US and Europe. This reliance on generics means the company is susceptible to significant pricing pressures, impacting profit margins. For instance, in fiscal year 2023, the generics segment continued to be a significant revenue driver, but faced headwinds from increased competition. \u003c\/p\u003e\n\u003cp\u003eSustaining growth and profitability in this environment requires a robust and consistently replenished pipeline of new product approvals. Furthermore, operational efficiency in manufacturing is paramount to control costs and maintain a competitive edge. Strides Pharma Science's ability to navigate these challenges is crucial for its long-term success in the pharmaceutical sector.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eIntense Competition:\u003c\/strong\u003e The generic drug market is characterized by numerous players, leading to price erosion and reduced profitability.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePricing Pressures:\u003c\/strong\u003e Regulated markets often experience aggressive pricing strategies from competitors and payers, impacting revenue.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePipeline Dependency:\u003c\/strong\u003e Continuous new product approvals are essential to offset the lifecycle decline of existing generics and maintain market share.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOperational Efficiency:\u003c\/strong\u003e Cost-effective manufacturing and supply chain management are critical for competitive pricing and margin preservation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUS Generics: Profitability and Inventory Pressures Mount\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStrides Pharma Science's significant reliance on the US generics market exposes it to substantial pricing pressures and intense competition. This vulnerability was evident in fiscal year 2024, where the segment faced headwinds impacting overall profitability. High inventory levels further exacerbate these challenges, potentially tying up working capital and increasing obsolescence risk.\u003c\/p\u003e\n\u003cp\u003eThe company's strategy to demerge its high-margin softgel business, while aimed at unlocking value, could temporarily impact consolidated margins. Navigating these pressures requires a consistently replenished product pipeline and robust operational efficiency to maintain competitive pricing and profitability.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY23 (INR Cr)\u003c\/th\u003e\n\u003cth\u003eFY24 (INR Cr)\u003c\/th\u003e\n\u003cth\u003eChange (%)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS Generics Revenue\u003c\/td\u003e\n\u003ctd\u003e~2,500\u003c\/td\u003e\n\u003ctd\u003e~2,300\u003c\/td\u003e\n\u003ctd\u003e-8.00%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Profit Margin (Consolidated)\u003c\/td\u003e\n\u003ctd\u003e~38%\u003c\/td\u003e\n\u003ctd\u003e~35%\u003c\/td\u003e\n\u003ctd\u003e-3.00 pp\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInventory Days\u003c\/td\u003e\n\u003ctd\u003e~120\u003c\/td\u003e\n\u003ctd\u003e~135\u003c\/td\u003e\n\u003ctd\u003e+15 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eStrides Pharma Science SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Strides Pharma Science SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. It provides a comprehensive overview of the company's internal strengths and weaknesses, as well as external opportunities and threats. This detailed report is ready for your strategic planning needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55610620608889,"sku":"strides-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/strides-swot-analysis.png?v=1754741593","url":"https:\/\/matrixbcg.com\/products\/strides-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}